SenseCare Medical Emerges as a New AI Healthcare Unicorn with $1.4B in Cumulative Funding and Files for IPO

Recently, investment and financing activities in the artificial intelligence sector have remained robust. Among these, “AI + Healthcare” has emerged as a prime avenue for intensive capital infusion, driven by its clear clinical needs and promising commercialization prospects. Against this backdrop, SenseTime Medical, a long-standing industry leader, has established multiple core competitive barriers by leveraging its full-stack proprietary large model technologies and market-validated business models.

Notably, the company has achieved the industry’s highest revenue per employee with a lean, elite team of just 100 members. Over 70% of its staff are dedicated to product development and R&D, boasting academic backgrounds from top-tier universities worldwide—including Stanford, Harvard, The Chinese University of Hong Kong, Tsinghua University, Peking University, and Shanghai Jiao Tong University—as well as practical experience at leading AI firms and internet giants. The team further features a high concentration of cutting-edge interdisciplinary talent with strong medical-engineering expertise. This rare combination has enabled the company to stand out in a competitive investment landscape, earning dual endorsement from premier medical institutions and leading investors.

Its benchmark collaboration with Singapore’s IHH Healthcare Group was selected as the sole medical case study for the “China’s Intelligence, Benefiting the World” case compendium featured at the opening ceremony of the World Artificial Intelligence Conference (WAIC), establishing it as a paradigmatic example of the “Chinese Solution” for AI-driven healthcare going global. Amid the intensifying global race in AI healthcare, SenseTime Medical is consistently leading industry development, driven by technological innovation, supported by ecosystem deployment, and guided by a global perspective.

With the successful completion of its Series A financing, SenseTime Medical has raised a cumulative total of RMB 1 billion within six months. With an increasingly clear capital market strategy, it has rapidly emerged as a notable pre-unicorn enterprise in the AI healthcare sector, pressing the “accelerator” on its comprehensive development.

On November 28, SenseTime Medical held a grand ceremony to mark the launch of its new journey, under the theme “Intelligence Ignites New Beginnings, Medicine Leads the Future.” At the event, Cheng Peng, Secretary of the Party Committee of the Shanghai Municipal Commission of Economy and Informatization, attended in person and delivered a speech. Three academicians—Academician Lin Zhongqin, former President of Shanghai Jiao Tong University; Academician Fan Xianqun, Member of the Standing Committee of the Party Committee and Vice President of Shanghai Jiao Tong University; and Academician Ning Guang, President of Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine—attended and gave addresses. Meanwhile, Academician Shen Zuyao, Senior Vice President and Dean of the Lee Kong Chian School of Medicine at Nanyang Technological University; Professor Dong Jiahong, Dean of Tsinghua University Clinical Medical College and President of Beijing Tsinghua Changgung Hospital; and Professor Dimitri Metaxas, an internationally renowned scholar and General Chair of CVPR 2026, delivered remarks via cloud connection. Together with authoritative experts from numerous hospitals and academic institutions, as well as representatives from over one hundred leading investment firms, they witnessed this milestone moment. The ceremony not only comprehensively showcased SenseTime Medical’s technological prowess and ecosystem strategy but also sent a strong signal and conveyed firm confidence to the capital markets regarding its leadership in the next generation of the smart healthcare revolution.

Market confidence in SenseTime Medical has received tangible validation at the capital level. Not long ago, SenseTime Medical announced the successful completion of a financing round amounting to hundreds of millions of yuan, with participation from multiple institutions including Lenovo Capital, Lianchuang Capital, Jiuxian Capital, and Shenran Investment. Coupled with the strategic investments received earlier this year from Infore Holdings (affiliated with Midea Group) and People’s Medical Publishing House Technology Development Company (a subsidiary of the People’s Medical Publishing House Group), the company’s fundraising demonstrates a pronounced Matthew effect and leading-market advantage. This stands in contrast to an environment where large-model applications are gaining momentum yet capital remains cautious. Unannounced financing rounds are reportedly reaching new highs.

Notably, each funding round for SenseTime Medical represents not only a substantial capital injection but also a deep integration into its strategic ecosystem. Representatives from investing institutions such as People's Medical Publishing House Science and Technology Development, Lenovo Capital, Infore Holdings, and BlueRun Ventures participated extensively in the event and engaged in in-depth discussions on the platform value and ecological synergy of AI healthcare during the "Industry and Capital Market Special Session" roundtable. Liang Ying, Managing Director of Lenovo Capital, emphasized in her speech that “SenseTime Medical’s full product line has been integrated into Lenovo SSG (Solutions & Services Group)’s omni-channel network. Meanwhile, SenseTime Medical’s products are being adapted to various Lenovo hardware offerings, achieving strong complementarity through software-hardware integration. Both parties are committed to establishing SenseTime Medical as a core stronghold within the healthcare sector, collaborating with all stakeholders to drive development and technological advancement in the global healthcare industry.”

The collaborative empowerment by industry partners is accelerating the integration and iteration of SenseTime’s medical AI technologies in real-world clinical settings, successfully building a critical bridge from R&D to industrial implementation. In early 2025, SenseTime Medical successfully deployed “SenseCare” at Heyou Hospital, a premier private healthcare institution under the Midea Group.^®“Smart Diagnosis and Treatment Platform” has launched 15 AI-assisted diagnostic applications, providing robust support for the diagnosis of complex diseases.

Moreover, SenseTime Medical is also making forward-looking strides in the fields of medical education and training as well as health insurance. Zhao Zhirui, General Manager of the Technology Development Company at People’s Medical Publishing House (PMPH), mentioned during a roundtable discussion that PMPH has engaged in deep collaborative explorations with SenseTime Medical across multiple domains to upgrade and enhance medical publishing and education. First, in collaboration with the Higher Education Department of the Ministry of Education and other entities, they are pooling top-tier experts to jointly build a Chinese library of simulated medical case studies and develop a trustworthy foundational large model for medicine, thereby bridging the gap between medical student education and clinical practice. Second, based on this model, they have constructed surgical training models covering 34 categories and 107 specialties, which have been piloted in multiple regions; these tools improve the learning efficiency of healthcare professionals and reduce medical costs. Third, in coordination with the National Healthcare Security Administration, they are conducting cost accounting for specific diseases using case data, thereby facilitating synergy between health insurance providers and healthcare institutions.

Other roundtable panelists, including Shi Chen, President of Infore Investment, and Rong Jing, Managing Director at BlueRun Ventures, also shared compelling industry insights and their perspectives on SenseTime Medical. Platform-based strategy, lightweight solutions, and innovative business models were among the most frequently mentioned keywords.

Currently, professional AI investors are primarily focused on the transformative value of technology for business models. Unlike overseas markets, the traditional medical software sales model in China suffers from pain points such as high costs and heavy reliance on customization, a limitation that SenseTime Medical is breaking through with its strategic layout. Investors place particular emphasis on its model generation platform. For instance, the company has developed a standardized multimodal large model for pathology based on over 300,000 pathological datasets, which can be sold directly to hospitals with delivery completed within three days. Physicians do not need specialized AI knowledge; they can independently train exclusive models using only simple, minimal medical annotations. This model not only escapes the high-cost dilemma of traditional customized implementation but also addresses pain points related to data privacy and security, opening up new possibilities for the commercialization of medical AI. These are among the many reasons why investors are bullish on SenseTime Medical.

Following a clear commercialization trajectory, SenseTime Medical has further proposed and constructed the “Medical World Model,” driving large models to transcend pure text-based interaction and enter highly realistic digital clinical environments. As Zhang Shaoting, CEO of SenseTime Medical, explained in his keynote address: “We are advancing medical AI from ‘textual reasoning’ to ‘world simulation,’ committed to building a digital foundation for future hospitals that enables continuous learning and autonomous evolution.” The accumulation and subsequent breakthrough of technologies have once again positioned SenseTime Medical at the forefront of global advancements in AI-driven healthcare.

While gaining recognition from diversified industrial capital, SenseTime Healthcare’s foundational technological cornerstone and ecosystem support stem from the continuous empowerment provided by SenseTime Group. Xu Li, Chairman and CEO of the Group, attended the event in person and reaffirmed in his speech that SenseTime Healthcare is a core extension of the Group’s “1+X” strategic ecosystem, with the Group serving as its most robust technical backbone and steadfast strategic partner. He further expressed his vision, stating, “The integration of artificial intelligence and healthcare holds a promising future. We believe that SenseTime Healthcare will not only achieve a complete commercial loop but also make greater contributions to empowering human health.”

Realizing this vision urgently requires the support of next-generation AI technology paradigms. Driven by top-level designs such as the “14th Five-Year Plan for Digital Economy Development,” China’s healthcare system is undergoing a profound “evolution” from informatization to intelligence, opening up vast market opportunities for companies with forward-looking technological layouts. According to Frost & Sullivan, the market size of AI healthcare in China is projected to surge from the tens of billions to the hundreds of billions of yuan within the next decade, with a compound annual growth rate (CAGR) of 43.1%.

Seizing this structural opportunity, SenseTime Medical is gradually emerging as the “Designer and Enabler of ‘Future Hospitals’ Driven by Large Healthcare Models,” leveraging its globally leading AI technologies and deep industry expertise. The company not only strengthens its “integration of general and specialized capabilities” technical framework by delving into key technologies of multimodal large models but also actively explores and advances the implementation path of healthcare “World Models.” This initiative aims to build an intelligent system capable of deeply understanding, simulating, and continuously optimizing real-world medical scenarios, thereby creating future smart hospitals with autonomous learning and self-evolution capabilities. Currently, SenseTime Medical has established a unique “1+2+N” technology and product ecosystem. With its self-developed “Dayi” large healthcare language model serving as the intelligent core, and supported by the dual middle-platform engines—the “Dayi Bots Agent Development Platform” and the “Multimodal Foundation Model Application Production Platform”—it forms a closed loop of “data-model-scenario-industry.” This approach transforms technological empowerment into operational and iterable intelligent assets for hospitals, laying an AI foundation for the autonomous evolution of smart hospital development.

Taking Shanghai Pulmonary Hospital, affiliated with Tongji University, as an example, and leveraging SenseTime Medical’s dual-middle-platform architecture, the hospital has not only achieved intelligent preliminary screening and assisted diagnosis of pathological images—reducing report generation time by nearly 50%—but also rapidly incubated multiple AI-assisted diagnostic models for pleural and peritoneal fluid cytology, bronchial brush cytology, and lung biopsy cytology, relying on its “Multimodal Foundation Model Application Production Platform.” Notably, in the “frozen nodule” research project, the platform supported the hospital in completing high-quality annotation of 294 cases, conducting over 200 rounds of model training, and continuously optimizing and iterating the models. This fully demonstrates the hospital’s capability for “independent development and autonomous evolution” built upon SenseTime’s technological foundation, marking a transition from mere “system deployment” to sustainable “ecosystem growth.”

Ultimately, by deploying hundreds of scenario-based applications covering the entire “doctor-patient-management-research” value chain, SenseTime Healthcare has systematically achieved value integration from underlying technologies to top-level business operations. This advancement is driving smart hospitals from isolated points of intelligence toward full-chain collaboration, and from static systems to a continuously evolving future paradigm. As more AI applications and technical services are implemented, SenseTime Healthcare will further establish a closed-loop service ecosystem spanning individual hospitals, regional medical consortia, and consumer-side health management. This will build a self-reinforcing growth flywheel characterized by data-driven decision-making, intelligent collaboration, scenario integration, and shared value. On the new trajectory toward a RMB 100 billion-scale AI healthcare market, SenseTime Healthcare is not only a pioneer in new technologies but also a key driver committed to integrating a new smart healthcare ecosystem and reconstructing industrial value, guided by the vision of “World Models.”